Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 1,500 shares at $51.21 ($77K) on 2017-02-01, disclosed to the SEC on 2017-02-06.
Open-market sale of $77k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-01-10 | $75K | — | Filing → |
| KITE | SELL | 2016-12-22 | $36K | — | Filing → |